Ensacove (ensartinib)

News alerts, weekly reports and conference planners

Company:

Betta Pharma

Drug class:

ALK inhibitor

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ensartinib Sensitive: C1 - Off-label ensartinib Sensitive : C1	ensartinib Sensitive: C1 - Off-label ensartinib Sensitive : C1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	ensartinib Sensitive: C2 – Inclusion Criteria ensartinib Sensitive : C2	ensartinib Sensitive: C2 – Inclusion Criteria ensartinib Sensitive : C2
ALK-KIF5B fusion	Non Small Cell Lung Cancer	ALK-KIF5B fusion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
ALK E1210K	Non Small Cell Lung Cancer	ALK E1210K	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
ALK G1269A	Non Small Cell Lung Cancer	ALK G1269A	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
EML4_E6-ALK_E18(V3)	Non Small Cell Lung Cancer	EML4_E6-ALK_E18(V3)	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
ALK-PPFIBP1 fusion	Non Small Cell Lung Cancer	ALK-PPFIBP1 fusion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-EML4_V3	Non Small Cell Lung Cancer	ALK-EML4_V3	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK T1151M	Non Small Cell Lung Cancer	ALK T1151M	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK L1152V	Non Small Cell Lung Cancer	ALK L1152V	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
ALK F1174L	Non Small Cell Lung Cancer	ALK F1174L	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK F1174V	Non Small Cell Lung Cancer	ALK F1174V	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-EML4_V1	Non Small Cell Lung Cancer	ALK-EML4_V1	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-EML4_V2	Non Small Cell Lung Cancer	ALK-EML4_V2	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-EML4_V5	Non Small Cell Lung Cancer	ALK-EML4_V5	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-EML4_V5a	Non Small Cell Lung Cancer	ALK-EML4_V5a	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK C1156Y	Non Small Cell Lung Cancer	ALK C1156Y	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-HIP1 fusion	Non Small Cell Lung Cancer	ALK-HIP1 fusion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK L1152R	Non Small Cell Lung Cancer	ALK L1152R	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK I1171T	Non Small Cell Lung Cancer	ALK I1171T	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK-DCHS1 fusion	Non Small Cell Lung Cancer	ALK-DCHS1 fusion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK T1151R	Non Small Cell Lung Cancer	ALK T1151R	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK amplification	Non Small Cell Lung Cancer	ALK amplification	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ALK I1171S	Non Small Cell Lung Cancer	ALK I1171S	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
TP53 mutation + ALK positive	Non Small Cell Lung Cancer	TP53 mutation + ALK positive	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3

Ensacove (ensartinib)

Associations
(42)

Associations
(42)

Ensacove (ensartinib)

Associations(42)

Associations(42)

Associations
(42)

Associations
(42)